



Created by Nature. Recreated by Science.™

NEWS RELEASE

CONTACT: Jane Stout, Cookerly Public Relations, 404-816-2037, jane@cookerly.com

**Vystar® Corporation and Alatech Healthcare, LLC Announce
FDA 510(k) Clearance for Exam Gloves Made with Vytex® NRL
New line of natural infection control products for caregivers and patients**

ATLANTA – July 29, 2009 – Vystar Corporation and Alatech Healthcare, LLC announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the first exam gloves manufactured with Vytex® Natural Rubber Latex (NRL). Alatech plans to introduce exam gloves made with Vytex NRL in the near future.

This marks the second Vytex NRL product to receive 510(k) clearance from the FDA in a new line of all natural infection control offerings. Alatech's Envy™ Natural Rubber Latex condom made with Vytex NRL received FDA clearance in May and is expected to be available later this year.

Vystar's patented Vytex NRL is an environmentally friendly material that contains virtually undetectable levels of the antigenic proteins that can cause an allergic response, while retaining and improving upon the desirable qualities of latex. Alatech's exam gloves made with Vytex will carry the protein label claim of less than 50 µg/dm² or less of total extractable protein per glove.

Vystar's CEO, William Doyle, said, "Vystar is excited to add exam gloves as the second Vytex NRL product with FDA 510(k) clearance. This is a significant and promising development for the future growth of our company since the glove category is the largest market for natural rubber latex. Because Vytex NRL is a natural, renewable product, Vystar is well positioned as a producer of eco-conscious raw materials for more than 40,000 products that contain natural rubber latex or petroleum-based synthetics.

Alatech President & CEO Lawrence Povlacs said, "Alatech views its relationship with Vystar as a strategic partnership for introducing a category of revolutionary natural products in the healthcare arena that represents the first line of defense in infection control for caregivers, patients and consumers globally."

According to the American Latex Allergy Association, approximately 17 percent of healthcare workers and up to three percent of the general population in the U.S. experience allergies or sensitivities to traditional latex.

More than 55 manufacturing trials are underway worldwide for gloves and other products made with Vytex NRL including medical and non-medical gloves, foam mattresses and pillows, bandages, adhesives and more. The Vystar Professional Support Team™ provides technical and marketing consultants who provide a wide range of expertise to manufacturing partners on compounding, conducting trials, interpreting results and developing standard operating procedures (SOPs) for successful manufacturing conversion and startup.

About Vystar Corporation

Based in Duluth, Ga., Vystar Corporation is a privately-held biotechnology company and the exclusive creator of Vytex Natural Rubber Latex (NRL). Vytex NRL is a patented, all natural raw material that significantly reduces antigenic proteins found in natural rubber latex and can be used in over 40,000 products. Vystar holds two U.S. patents, an additional pending application, and multiple international patent filings for Vytex NRL technology. In 2007, Vystar was named a Top 10 Innovative Technology Company in Georgia by the Technology Association of Georgia (TAG). For more information, visit www.vytex.com.

About Alatech Healthcare, LLC

Based in Eufaula, Ala., Alatech Healthcare, LLC is a leading manufacturer and supplier of condoms and latex gloves. For more information, visit www.alatechhealthcare.com.

Forward-looking Statements: Certain matters discussed in this press release are “forward-looking statements.” These forward-looking statements can generally be identified as such because the context of the statement will include words, such as Vystar Corporation “expects,” “should,” “believes,” “anticipates” or words of similar import. Similarly, statements that describe Vystar’s future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Vystar as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Vystar believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and Vystar does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

###